Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Rectal Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neutropenia 2Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2mCRC 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × trifluridine tipiracil drug combination × 1 year × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡